U.S. Health Care REITs Stock News

If you are looking at AtriCure and wondering whether the current share price reflects its true worth, you are not alone. Many investors are asking the same question right now. The stock recently closed at US$31.25, with returns of a 4.1% decline over 7 days, a 17.3% decline over 30 days and a 20.4% decline year to date, adding to a 19.3% decline over 1 year, a 21.7% decline over 3 years and a 51.0% decline over 5 years. These moves have put more attention on how AtriCure is being valued,...

Ramaco Resources reported fourth-quarter 2025 sales of US$128.01 million and a net loss of US$14.71 million, alongside a full-year 2025 net loss of US$51.45 million on sales of US$536.62 million, while also being served with a putative securities class action tied to disclosures about its Brook Mine rare earth project. At the same time, the company outlined progress at Brook Mine and highlighted stronger liquidity following recent financings, underlining how its rare earth ambitions and...

PROCEPT BioRobotics (NasdaqGM:PRCT) has overhauled its commercial model, implementing a major realignment of its sales organization and pricing strategy. The company has removed bulk purchase discounts and created a dedicated team focused on driving greater procedural adoption. These changes come alongside significant procedure growth and a reset in financial guidance, marking a key shift in how the company pursues profitability and market expansion. PROCEPT BioRobotics focuses on robotic...

If you are wondering whether Southwest Gas Holdings at around US$88 per share offers good value today, you are not alone; many investors are trying to work out what a fair price looks like. The stock has returned 0.7% over the last week, 7.6% over the past month, 10.0% year to date, 21.3% over one year, 62.5% over three years and 51.5% over five years, which naturally raises questions about how its current price lines up with its fundamentals. Recent news flow around regulated utilities, gas...

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...

Burford Capital (NYSE:BUR) rounded out FY 2025 with Q4 revenue of US$33.4 million and a basic EPS loss of US$0.17, as quarterly earnings swung back into the red despite a profitable first half. The company has seen quarterly revenue move from US$244.9 million and EPS of US$0.62 in Q3 2024 to US$178.0 million and EPS of US$0.40 in Q2 2025, and then to US$64.7 million with an EPS loss of US$0.09 in Q3 2025 before landing at the latest Q4 figures. This sets up a results season in which investors...

If you are wondering whether Thermon Group Holdings is still attractively priced or already reflecting most of its potential, you are in the right place for a valuation-focused look at the stock. The share price, last closing at US$50.78, comes with a mixed return profile, with a 0.5% decline over 7 days, a 16.9% gain over 30 days, 34.9% year to date, 72.1% over 1 year, 84.6% over 3 years and 136.7% over 5 years. Recent price action sits alongside ongoing news flow around Thermon Group...

D-Market Elektronik Hizmetler ve Ticaret (NasdaqGS:HEPS) has wrapped up FY 2025 with Q4 revenue of approximately ₺30.3b and a net loss of about ₺3.2b, capping a year in which trailing twelve month revenue reached roughly ₺84.7b alongside a total net loss of around ₺5.7b. The company reported quarterly revenue increasing from about ₺20.4b in Q4 2024 to ₺30.3b in Q4 2025, while quarterly net losses widened from roughly ₺724m to about ₺3.2b over the same period. EPS on a trailing twelve month...

Alexander & Baldwin (ALEX) has wrapped up FY 2025 with fourth quarter revenue of US$43.8 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$206.7 million and EPS of US$0.89. Over the last six quarters, the company has seen quarterly revenue move from US$63.2 million in Q4 2024 to US$56.8 million in Q1 2025 and down to US$43.8 million in Q4 2025, while quarterly EPS moved from US$0.18 to US$0.29 and then US$0.05. This sets up a mixed backdrop for a stock trading at...

Golden Entertainment (GDEN) has wrapped up FY 2025 with Q4 revenue of US$155.6 million and a basic EPS loss of US$0.33, alongside net income excluding extra items of a US$8.5 million loss. Over recent periods, the company has seen quarterly revenue move between US$154.8 million and US$164.2 million, while EPS has swung from a profit of US$0.18 in Q3 2024 to a loss of US$0.33 in Q4 2025. This leaves investors watching how quickly margins can stabilize from here. See our full analysis for...

A Kinsale Capital Group (NYSE:KNSL) board director recently sold shares, drawing fresh attention to insider activity at the company. Management has flagged moderating premium growth and increasing competition in its core markets. Together, these updates point to a changing operating backdrop that investors are now reassessing. Kinsale Capital Group, trading at $389.67 as of the last close, comes into this news with a mixed recent record. The stock is up 4.4% over the past week, flat over...

RAPT Therapeutics (RAPT) has drawn fresh attention after a sharp move in its share performance over the past 3 months. This has prompted investors to reassess the clinical stage biotech’s risk and reward profile. See our latest analysis for RAPT Therapeutics. At a share price of US$57.96, RAPT Therapeutics has shifted sharply over the past year, with a very large 1 year total shareholder return and a long term total shareholder return that remains negative. This suggests that recent momentum...

Ryerson Holding, now trading as NYSE:RYZ, has completed its merger with Olympic Steel. The combined company has introduced substantial changes to its executive leadership team and Board of Directors. The merger includes a stock ticker change and material amendments to Ryerson Holding's credit agreement. For you as an investor, this represents a meaningful reset for a metals service center business that now blends Ryerson Holding and Olympic Steel under the NYSE:RYZ ticker. Both companies...

If you are wondering whether Cardinal Infrastructure Group is priced attractively today, you are not alone. The stock has been on many investors' watchlists as questions around its fair value grow louder. The share price sits at US$33.05, with returns of 2.5% over the last 7 days, 19.2% over the past 30 days, and 46.1% year to date. This has sharpened interest in what is actually built into the current valuation. Recent coverage has focused on Cardinal Infrastructure Group's role in the...

Fastenal (NasdaqGS:FAST) reported a 59% year over year increase in CEO Daniel L. Florness's compensation in a new SEC filing. Multiple insiders have purchased Fastenal stock over the past six months. The company has been awarded nearly $8 million in government contracts over the last year. Fastenal, trading at around $45.68 per share, has seen its stock return 13.0% year to date and 25.9% over the past year, with longer term gains of 85.9% over three years and 133.3% over five years. In...

If you are wondering whether Farmers & Merchants Bank of Long Beach is priced attractively at around US$8,435 per share, you are not alone. This article is built to help you frame that question clearly. The stock has been relatively steady in the short term, with a 0.2% 7 day decline and returns of 1.0% over 30 days, 1.9% year to date and 50.9% over the last year, plus 29.0% over 3 years and 24.3% over 5 years. Recent coverage of Farmers & Merchants Bank of Long Beach has focused on its...

If you are looking at Bausch Health Companies and wondering whether the current share price reflects its underlying value, you are not alone. The stock last closed at US$6.04, with returns of 1.9% over the past week and 5.6% over the past month, against year to date and 1 year returns of 16.2% and 21.0% declines, and a 34.7% and 81.1% decline over 3 and 5 years respectively. These moves have kept valuation in focus for many investors, especially as headlines continue to frame Bausch Health...

In February 2026, Camping World Holdings reported fourth-quarter and full-year 2025 results showing quarterly revenue of US$1,173.56 million and a widening net loss of US$67.3 million, alongside a full-year net loss of US$89.8 million despite higher annual revenue of US$6,369.15 million. At the same time, the board paused Camping World’s regular quarterly cash dividend to prioritize reducing net debt leverage amid tax law changes and weaker profitability, marking a significant shift in how...

Ategrity Specialty Insurance Company Holdings (NYSE:ASIC) has authorized a new $50 million share repurchase program. The buyback plan allows the company to repurchase its common stock, subject to market conditions and other factors. This announcement adds a new capital deployment option alongside any existing uses of cash such as underwriting operations and potential growth initiatives. Ategrity Specialty Insurance Company Holdings focuses on specialty insurance, a segment where...

DiamondRock Hospitality (NasdaqGS:DRH) has announced the retirement of founding Chairman and inaugural CEO William W. McCarten after more than 20 years with the company. Bruce D. Wardinski has been appointed as the new non executive Chairman, marking a shift in board leadership. The company is also reducing the size of its board, signaling a change in its governance structure. For shareholders watching DiamondRock Hospitality at a share price of $10.33, this leadership handover comes after...

In February 2026, Larimar Therapeutics announced that the FDA granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, while the company advanced plans for an accelerated Biologics License Application supported by skin frataxin as a novel surrogate endpoint. This combination of expedited regulatory status and FDA alignment on using a new biomarker underscores how central nomlabofusp has become to Larimar’s clinical and regulatory...

Vaxart (VXRT) is drawing fresh attention ahead of its scheduled presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. Investors will be listening for pipeline and funding updates. See our latest analysis for Vaxart. Vaxart’s recent 34.83% 7 day share price return and 102.97% 90 day share price return point to building momentum ahead of the conference, even as the 5 year total shareholder return of 87.31% highlights longer term challenges. If...

PicS N.V. completed a US$434.3 million initial public offering. The company began trading on the Nasdaq Global Select Market under the ticker NasdaqGS:PICS. This is the first new stock listing by a Brazilian company in over four years. With its IPO now complete, PicS enters the public markets at a share price of $17.76 and a recent 7 day return of 17.6%. The listing of NasdaqGS:PICS also marks a return of Brazilian issuers to international equity markets after a multi year pause in new...

Terns Pharmaceuticals (TERN) has drawn attention after recent trading, with the stock closing at US$40.92. For investors, the clinical stage focus on oncology and obesity raises questions about how current pricing reflects trial progress and cash needs. See our latest analysis for Terns Pharmaceuticals. While the share price slipped around 1% on the day to US$40.92, it remains on a strong short term run, with a 16.61% 1 month share price return and a 45.57% 3 month share price return,...